Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxytocin
Drug ID BADD_D01652
Description Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.[A229008,A228593,A229108] Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues.[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.[A229108] Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage.[A229108,A229113] It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally.[A228593] It should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners.[A229113] Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.[A229008] It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.[A229013] Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.[A228593,A229098]
Indications and Usage Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern.[L31433] For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes.[A229018,L31433] Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.[L31433]
Marketing Status approved; vet_approved
ATC Code H01BB02
DrugBank ID DB00107
KEGG ID D00089
MeSH ID D010121
PubChem ID 439302
TTD Drug ID D0M3FJ
NDC Product Code 0641-6115; 41701-017; 70155-001; 42023-130; 41701-002; 0143-9743; 0143-9742; 55154-9584; 63323-012; 0641-6114; 60870-0438; 73212-021; 76617-011; 62991-3133; 75882-213; 42023-116; 14403-0015; 46600-0001; 49452-4956; 51927-0281; 64189-1202; 38779-2492; 51552-0631
UNII 1JQS135EYN
Synonyms Oxytocin | Ocytocin | Syntocinon | Pitocin
Chemical Information
Molecular Formula C43H66N12O12S2
CAS Registry Number 50-56-6
SMILES CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3C CCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervous system disorder17.02.10.001--Not Available
Postpartum haemorrhage24.07.03.003; 18.06.01.001--Not Available
Rash23.03.13.001--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.004--Not Available
Tachycardia02.03.02.007--Not Available
Uterine hypertonus21.07.03.004; 18.07.02.003--Not Available
Uterine rupture18.02.02.001; 12.01.15.001; 21.07.01.009--Not Available
Uterine spasm21.07.03.002--Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Vomiting07.01.07.003--
Water intoxication19.07.03.004; 14.05.06.004; 05.03.03.003--Not Available
Neonatal hyponatraemia18.04.06.005; 14.05.04.005--Not Available
Lymphatic disorder01.09.01.003--Not Available
Pelvic haematoma24.07.03.010; 21.07.04.001--Not Available
Foetal death18.01.02.003; 08.04.01.011--
Haemorrhage24.07.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Blood disorder01.05.01.004--Not Available
Effusion08.01.03.052--Not Available
Uterine hyperstimulation21.07.03.006; 18.07.02.008--Not Available
Brain injury19.07.03.007; 17.11.01.003--Not Available
Neonatal seizure17.12.03.038; 18.04.04.019--Not Available
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene